142 related articles for article (PubMed ID: 38714355)
41. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
Galvin R; Watson AL; Largaespada DA; Ratner N; Osum S; Moertel CL
Curr Oncol Rep; 2021 Mar; 23(4):45. PubMed ID: 33721151
[TBL] [Abstract][Full Text] [Related]
42. Antiseizure effect of MEK inhibitor in a child with neurofibromatosis type 1-Developmental and epileptic encephalopathy and optic pathway glioma.
Barrière S; Faure-Conter C; Leblond P; Philippe M; des Portes V; Lion François L; de Bellescize J; Sabatier I
Epileptic Disord; 2024 Feb; 26(1):133-138. PubMed ID: 37983638
[TBL] [Abstract][Full Text] [Related]
43. Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes.
Sandsmark DK; Zhang H; Hegedus B; Pelletier CL; Weber JD; Gutmann DH
Cancer Res; 2007 May; 67(10):4790-9. PubMed ID: 17510408
[TBL] [Abstract][Full Text] [Related]
44. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
45. Quantitative analysis of NF1 and OMGP gene transcripts in sporadic gliomas, sporadic meningiomas and neurofibromatosis type 1-associated plexiform neurofibromas.
Peters N; Waha A; Wellenreuther R; Friedrich RE; Mautner VF; Hoffmeyer S; Lenartz D; Schramm J; Wiestler OD; von Deimling A
Acta Neuropathol; 1999 Jun; 97(6):547-51. PubMed ID: 10378372
[TBL] [Abstract][Full Text] [Related]
46. Clinicopathologic implications of NF1 gene alterations in diffuse gliomas.
Vizcaíno MA; Shah S; Eberhart CG; Rodriguez FJ
Hum Pathol; 2015 Sep; 46(9):1323-30. PubMed ID: 26190195
[TBL] [Abstract][Full Text] [Related]
47. Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity.
Brown JA; Gianino SM; Gutmann DH
J Neurosci; 2010 Apr; 30(16):5579-89. PubMed ID: 20410111
[TBL] [Abstract][Full Text] [Related]
48. MEK inhibitors in RASopathies.
Bergqvist C; Wolkenstein P
Curr Opin Oncol; 2021 Mar; 33(2):110-119. PubMed ID: 33395032
[TBL] [Abstract][Full Text] [Related]
49. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway.
Feldkamp MM; Angelov L; Guha A
Surg Neurol; 1999 Feb; 51(2):211-8. PubMed ID: 10029430
[TBL] [Abstract][Full Text] [Related]
50. Mutation of
Harigai R; Sato R; Hirose C; Takenouchi T; Kosaki K; Hirose T; Saya H; Arima Y
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625983
[TBL] [Abstract][Full Text] [Related]
51. Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner.
Turbyville TJ; Gürsel DB; Tuskan RG; Walrath JC; Lipschultz CA; Lockett SJ; Wiemer DF; Beutler JA; Reilly KM
Mol Cancer Ther; 2010 May; 9(5):1234-43. PubMed ID: 20442305
[TBL] [Abstract][Full Text] [Related]
52. Platelet-Derived Growth Factor Receptor and Ionizing Radiation in High Grade Glioma Cell Lines.
Alexandru O; Sevastre AS; Castro J; Artene SA; Tache DE; Purcaru OS; Sfredel V; Tataranu LG; Dricu A
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547056
[TBL] [Abstract][Full Text] [Related]
53. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.
Woodfield SE; Zhang L; Scorsone KA; Liu Y; Zage PE
BMC Cancer; 2016 Mar; 16():172. PubMed ID: 26925841
[TBL] [Abstract][Full Text] [Related]
54. Germline and somatic NF1 gene mutations in plexiform neurofibromas.
Upadhyaya M; Spurlock G; Monem B; Thomas N; Friedrich RE; Kluwe L; Mautner V
Hum Mutat; 2008 Aug; 29(8):E103-11. PubMed ID: 18484666
[TBL] [Abstract][Full Text] [Related]
55. NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.
Toonen JA; Anastasaki C; Smithson LJ; Gianino SM; Li K; Kesterson RA; Gutmann DH
Hum Mol Genet; 2016 May; 25(9):1703-13. PubMed ID: 26908603
[TBL] [Abstract][Full Text] [Related]
56. The NF1 gene revisited - from bench to bedside.
Yap YS; McPherson JR; Ong CK; Rozen SG; Teh BT; Lee AS; Callen DF
Oncotarget; 2014 Aug; 5(15):5873-92. PubMed ID: 25026295
[TBL] [Abstract][Full Text] [Related]
57. Neurofibromatosis type 1 (NF1): diagnosis and management.
Ferner RE; Gutmann DH
Handb Clin Neurol; 2013; 115():939-55. PubMed ID: 23931823
[TBL] [Abstract][Full Text] [Related]
58. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes.
Dasgupta B; Li W; Perry A; Gutmann DH
Cancer Res; 2005 Jan; 65(1):236-45. PubMed ID: 15665300
[TBL] [Abstract][Full Text] [Related]
59.
Pucciarelli D; Angus SP; Huang B; Zhang C; Nakaoka HJ; Krishnamurthi G; Bandyopadhyay S; Clapp DW; Shannon K; Johnson GL; Nakamura JL
Mol Cancer Ther; 2020 Nov; 19(11):2382-2395. PubMed ID: 32847978
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
